Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Health And Wellness Trademarks Review, April 16, 2019

Executive Summary

Trademarks registered and published for opposition with USPTO in Class 3 – cosmetics and cleaning Preps, and Class 5 –pharmaceuticals. Marks for vitamin, mineral and supplement products also are registered or published for opposition in both Class 3 and Class 5.

Trademarks are registered and published for opposition with the US Patent and Trademark Office are published weekly in the agency's Official Gazette.

Trademarks Class 3 include cosmetics and cleaning preps and class 5 includes pharmaceuticals. Marks for vitamin, mineral and supplement products also are registered or published for opposition in both Class 3 and Class 5. The list of Class 3 and Class 5 entries from the April 16 issue of the Official Gazette are linked below in downloadable and searchable PDFs.

Health And Wellness Weekly Trademark Review: April 16, 2019

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS148738

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel